erlotinib has been researched along with atropine in 3 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 26,711 | 1,259 | 1,697 |
| Protein | Taxonomy | erlotinib (IC50) | atropine (IC50) |
|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 21.41 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.012 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.0067 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.0007 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0009 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.001 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0015 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0021 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.354 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for erlotinib and atropine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for erlotinib and atropine
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |